Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Learn from China (Asia)

This article was originally published in PharmAsia News

Executive Summary

China's recent quality problems with food and pharmaceutical exports have tarnished its reputation and could become a concern for all of Asia's pharmaceutical industries. For instance, India imports large quantities of raw materials for antibiotics from China, and this has drawn concern from Indian and U.S. authorities. In fact, India exported around $800 million in drugs and pharmaceutical ingredients to the United States in 2006. This trade volume ranks above the $675 million of such products sent to the United States by China. Indian pharmaceutical laws are not evenly enforced or well-funded across all provinces. This one day may result in negative world attention such as the scandals experienced recently by China. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel